Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Cell-Free microRNA-214 From Urine as a Biomarker for Non-Muscle-Invasive Bladder Cancer.

Kim SM, Kang HW, Kim WT, Kim YJ, Yun SJ, Lee SC, Kim WJ.

Korean J Urol. 2013 Nov;54(11):791-6. doi: 10.4111/kju.2013.54.11.791. Epub 2013 Nov 6.

2.

Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer.

Zhang X, Zhang Y, Liu X, Fang A, Wang J, Yang Y, Wang L, Du L, Wang C.

Oncotarget. 2016 Jan 19;7(3):3255-66. doi: 10.18632/oncotarget.6487.

3.

Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer.

Yun SJ, Jeong P, Kim WT, Kim TH, Lee YS, Song PH, Choi YH, Kim IY, Moon SK, Kim WJ.

Int J Oncol. 2012 Nov;41(5):1871-8. doi: 10.3892/ijo.2012.1622. Epub 2012 Sep 6.

PMID:
22961325
4.

Downregulation of urinary cell-free microRNA-214 as a diagnostic and prognostic biomarker in bladder cancer.

Wang J, Zhang X, Wang L, Dong Z, Du L, Yang Y, Guo Y, Wang C.

J Surg Oncol. 2015 Jun;111(8):992-9. doi: 10.1002/jso.23937. Epub 2015 May 14.

PMID:
25975233
5.

Circulating miR-205: a promising biomarker for the detection and prognosis evaluation of bladder cancer.

Fang Z, Dai W, Wang X, Chen W, Shen C, Ye G, Li L.

Tumour Biol. 2016 Jun;37(6):8075-82. doi: 10.1007/s13277-015-4698-y. Epub 2015 Dec 29.

PMID:
26715266
6.

Cell-free microRNA expression signatures in urine serve as novel noninvasive biomarkers for diagnosis and recurrence prediction of bladder cancer.

Du L, Jiang X, Duan W, Wang R, Wang L, Zheng G, Yan K, Wang L, Li J, Zhang X, Pan H, Yang Y, Wang C.

Oncotarget. 2017 Jun 20;8(25):40832-40842. doi: 10.18632/oncotarget.16586.

7.

Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer.

Jiang X, Du L, Wang L, Li J, Liu Y, Zheng G, Qu A, Zhang X, Pan H, Yang Y, Wang C.

Int J Cancer. 2015 Feb 15;136(4):854-62. doi: 10.1002/ijc.29041. Epub 2014 Jul 1.

8.

Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer?

Scheffer AR, Holdenrieder S, Kristiansen G, von Ruecker A, Müller SC, Ellinger J.

World J Urol. 2014 Apr;32(2):353-8. doi: 10.1007/s00345-012-1010-2. Epub 2012 Dec 25.

PMID:
23266581
9.

mRNA Expression of S100A8 as a Prognostic Marker for Progression of Non-Muscle-Invasive Bladder Cancer.

Ha YS, Kim MJ, Yoon HY, Kang HW, Kim YJ, Yun SJ, Lee SC, Kim WJ.

Korean J Urol. 2010 Jan;51(1):15-20. doi: 10.4111/kju.2010.51.1.15. Epub 2010 Jan 21.

10.

Is urinary soluble Fas an independent predictor of non-muscle-invasive bladder cancer? A prospective chart study.

Yang H, Li H, Wang Z, Gao J, Guo Y.

Urol Int. 2013;91(4):456-61. doi: 10.1159/000350752. Epub 2013 Aug 14.

PMID:
23948854
11.

microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer.

Pignot G, Cizeron-Clairac G, Vacher S, Susini A, Tozlu S, Vieillefond A, Zerbib M, Lidereau R, Debre B, Amsellem-Ouazana D, Bieche I.

Int J Cancer. 2013 Jun 1;132(11):2479-91. doi: 10.1002/ijc.27949. Epub 2013 Feb 25.

12.

Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer.

Shim UJ, Lee IS, Kang HW, Kim J, Kim WT, Kim IY, Ryu KH, Choi YH, Moon SK, Kim YJ, Yun SJ, Lee SC, Kim WJ.

Korean J Urol. 2013 Sep;54(9):631-7. doi: 10.4111/kju.2013.54.9.631. Epub 2013 Sep 10.

13.

Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.

Kim JS, Chae Y, Ha YS, Kim IY, Byun SS, Yun SJ, Kim WJ.

Clin Genitourin Cancer. 2012 Jun;10(2):114-20. doi: 10.1016/j.clgc.2011.12.003. Epub 2012 Feb 28.

PMID:
22382007
14.

GSTT1 as a prognosticator for recurrence and progression in patients with non-muscle-invasive bladder cancer.

Ha YS, Yan C, Lym MS, Jeong P, Kim WT, Kim YJ, Yun SJ, Lee SC, Moon SK, Choi YH, Kim WJ.

Dis Markers. 2010;29(2):81-7. doi: 10.3233/DMA-2010-0729.

15.

Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.

Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG.

BJU Int. 2012 Feb;109(4):496-505. doi: 10.1111/j.1464-410X.2011.10880.x. Review.

16.

Urinary cell microRNA-based prognostic classifier for non-muscle invasive bladder cancer.

Ingelmo-Torres M, Lozano JJ, Izquierdo L, Carrion A, Costa M, Gómez L, Ribal MJ, Alcaraz A, Mengual L.

Oncotarget. 2017 Mar 14;8(11):18238-18247. doi: 10.18632/oncotarget.15315.

17.
18.

Effects of Previous or Synchronous Non-Muscle Invasive Bladder Cancer on Clinical Results after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multi-Institutional Study.

Kim BW, Ha YS, Lee JN, Kim HT, Kim TH, Lee JK, Byun SS, Choi YD, Kang HW, Yun SJ, Kim WJ, Kwon YS, Kwon TG.

Urol J. 2015 Sep 4;12(4):2233-9.

19.

Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer.

Wang S, Xue S, Dai Y, Yang J, Chen Z, Fang X, Zhou W, Wu W, Li Q.

Diagn Pathol. 2012 Nov 22;7:159. doi: 10.1186/1746-1596-7-159.

20.

Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.

Lin YL, Wang YL, Ma JG, Li WP.

J Exp Clin Cancer Res. 2014 Aug 22;33:68. doi: 10.1186/s13046-014-0068-7.

Supplemental Content

Support Center